Form D · Biotechnology

DEXCOM INC

San Diego, CA · CIK 0001093557

Offering snapshot reported May 18, 2016 · SEC filing

Reported sold
$7.23M
Offering amount: $7.23M
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 2, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 18, 2016Initial$7,225,664No comparison2SEC filing
Apr 12, 2012Initial$3,964,019No comparison30SEC filing
Apr 12, 2012Amendment$3,964,019$0vs Apr 12, 201230SEC filing
Feb 14, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-263377

Source: Form D, filed May 18, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steven R. Altman Director
Nicholas Augustinos Director
Andrew K. Balo Executive
Martin L. Doordan Director
Richard Doubleday Executive
Mark Foletta Director
Terrance H. Gregg Director, Executive
Barbara E. Kahn Director
John D. Lister Executive
Jonathan T. Lord Director
Jeffrey Moy Executive
Steven R. Pacelli Executive
Jess Roper Executive
Kevin Sayer Director, Executive
Jay S. Skyler Director
Eric Topol Director
Jorge Valdes Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6340 Sequence Drive
San Diego, CA, 92121